Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 4
2006 3
2007 1
2009 2
2010 3
2012 1
2013 1
2014 3
2015 3
2016 2
2017 2
2018 3
2019 6
2021 8
2022 4
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M, Wimberger P, Forberger A, Tesch H, Jackisch C, Schmatloch S, Reinisch M, Solomayer EF, Schmitt WD, Hanusch C, Fasching PA, Lübbe K, Solbach C, Huober J, Rhiem K, Marmé F, Reimer T, Schmidt M, Sinn BV, Janni W, Stickeler E, Michel L, Stötzer O, Hahnen E, Furlanetto J, Seiler S, Nekljudova V, Untch M, Loibl S. Denkert C, et al. Among authors: schmitt wd. Lancet Oncol. 2021 Aug;22(8):1151-1161. doi: 10.1016/S1470-2045(21)00301-6. Epub 2021 Jul 9. Lancet Oncol. 2021. PMID: 34252375
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S. Denkert C, et al. Among authors: schmitt wd. Lancet Oncol. 2018 Jan;19(1):40-50. doi: 10.1016/S1470-2045(17)30904-X. Epub 2017 Dec 7. Lancet Oncol. 2018. PMID: 29233559
LRP1B-a prognostic marker in tubo-ovarian high-grade serous carcinoma.
Kolb S, Hoffmann I, Monjé N, Dragomir MP, Jank P, Bischoff P, Keunecke C, Pohl J, Kunze CA, Marchenko S, Schmitt WD, Kulbe H, Sers C, Sehouli J, Braicu EI, Denkert C, Darb-Esfahani S, Horst D, Sinn BV, Taube ET. Kolb S, et al. Among authors: schmitt wd. Hum Pathol. 2023 Nov;141:158-168. doi: 10.1016/j.humpath.2023.09.001. Epub 2023 Sep 22. Hum Pathol. 2023. PMID: 37742945 Free article.
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma.
Jank P, Leichsenring J, Kolb S, Hoffmann I, Bischoff P, Kunze CA, Dragomir MP, Gleitsmann M, Jesinghaus M, Schmitt WD, Kulbe H, Sers C, Stenzinger A, Sehouli J, Braicu IE, Westhoff C, Horst D, Denkert C, Gröschel S, Taube ET. Jank P, et al. Among authors: schmitt wd. J Ovarian Res. 2023 Jul 31;16(1):150. doi: 10.1186/s13048-023-01239-6. J Ovarian Res. 2023. PMID: 37525239 Free PMC article.
RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial.
Link T, Blohmer JU, Schmitt WD, Kuhlmann JD, Just M, Untch M, Stotzer O, Fasching PA, Thill M, Reinisch M, Schneeweiss A, Wimberger P, Seiler S, Huober J, Jackisch C, Rhiem K, Hanusch C, Sinn BV, Nekljudova V, Loibl S, Denkert C. Link T, et al. Among authors: schmitt wd. Clin Cancer Res. 2023 Nov 14;29(22):4606-4612. doi: 10.1158/1078-0432.CCR-23-1801. Clin Cancer Res. 2023. PMID: 37725572
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.
Hoffmann I, Dragomir MP, Monjé N, Keunecke C, Kunze CA, Schallenberg S, Marchenko S, Schmitt WD, Kulbe H, Sehouli J, Braicu IE, Jank P, Denkert C, Darb-Esfahani S, Horst D, Sinn BV, Sers C, Bischoff P, Taube ET. Hoffmann I, et al. Among authors: schmitt wd. Neoplasia. 2023 Oct;44:100934. doi: 10.1016/j.neo.2023.100934. Epub 2023 Sep 11. Neoplasia. 2023. PMID: 37703626 Free PMC article.
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Fasching PA, Just M, Hanusch C, Hackmann J, Blohmer JU, Rhiem K, Schmitt WD, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Loibl S. Untch M, et al. Among authors: schmitt wd. J Clin Oncol. 2019 Sep 1;37(25):2226-2234. doi: 10.1200/JCO.18.01842. Epub 2019 May 13. J Clin Oncol. 2019. PMID: 31082269 Clinical Trial.
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging.
Gonçalves JPL, Bollwein C, Noske A, Jacob A, Jank P, Loibl S, Nekljudova V, Fasching PA, Karn T, Marmé F, Müller V, Schem C, Sinn BV, Stickeler E, van Mackelenbergh M, Schmitt WD, Denkert C, Weichert W, Schwamborn K. Gonçalves JPL, et al. Among authors: schmitt wd. Int J Mol Sci. 2023 Feb 2;24(3):2860. doi: 10.3390/ijms24032860. Int J Mol Sci. 2023. PMID: 36769215 Free PMC article.
Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.
Kassuhn W, Klein O, Darb-Esfahani S, Lammert H, Handzik S, Taube ET, Schmitt WD, Keunecke C, Horst D, Dreher F, George J, Bowtell DD, Dorigo O, Hummel M, Sehouli J, Blüthgen N, Kulbe H, Braicu EI. Kassuhn W, et al. Among authors: schmitt wd. Cancers (Basel). 2021 Mar 25;13(7):1512. doi: 10.3390/cancers13071512. Cancers (Basel). 2021. PMID: 33806030 Free PMC article.
46 results